Company says acquisition demonstrates continued commitment to structural heart portfolio
Approval grants MR-conditional labeling to all EMBLEM S-ICD Systems, further expanding the company’s ImageReady™ portfolio
Full-Body MRI access expands Spinal Cord Stimulation offering and brings customized therapy to more patients suffering from chronic pain
Ureteroscopes are used 4600 times a day to examine the urinary tract. Boston Scientific is claiming a first with its new disposable offering, which does sound like a game changer
ZelanteDVT catheter is the first AngioJet catheter designed specifically to treat DVT
Boston Scientific Corporation is to acquire Xlumena, Inc., developer of Endoscopic Ultrasound-guided transluminal drainage devices
Boston Scientific will be hoping its new S-ICD will prove popular based on its advantages over conventionally placed leads
First-Of-Its-Kind alternative to long-term Warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation
The new Extended Longevity ICDs, featuring EnduraLife battery technology promise almost twelve years
Whatever the value of retrospective data, Boston Scientific is touting results that make a solid case for its Precision Spectra spinal cord stimulator system
Boston Scientific reports that its SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in the first successful U.S. pivotal trial of a bioabsorbable polymer stent.
When implanted with Boston Scientific’s INGEVITY™ leads, Boston Scientific’s ACCOLADE pacemakers are the first to enable patients to receive full-body MRI scans in both 1.5 Tesla and 3.0 Tesla systems.
Expert Panel review has culminateded in a vote in favour of Boston Scientific Corporation’s WATCHMAN™ Left Atrial Appendage Closure Device.
The family of the man who helped invent the ICD has been awarded $309 million against Boston Scientific, although appeals loom.
It’s good news/bad news for Boston Scientific’s Vagus Nerve Stimulation plans as a heart failure therapy. While efficacy endpoints suggested no outcome improvement, patients in the treatment group of the sham controlled study reported quality of life improvement.
Sounds like a plan. Combine the offerings of one of the Cardiovascular big boys with wire forming company’s expertise and FFR technology is likely to benefit.